MAIA Biotechnology (MAIA) News
NYSE: MAIAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.11-0.03 (-2.63%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MAIA news summary
We found 4 recent headlines mentioning MAIA Biotechnology (MAIA): 3 in the past week and 3 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, MAIA is down 2.63% at $1.11. The most recent story, "MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer", was published by Nasdaq on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest MAIA Biotechnology headlines
- MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung CancerMAIA Biotechnology, Inc. announced updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating its novel telomere-targeting therapy, ateganosine, as a third-line (3L)…Nasdaq
- MAIA Biotechnology Reports 88% Disease Control Rate In Expanded Phase 2 NSCLC Study(RTTNews) - MAIA Biotechnology, Inc. (MAIA) announced updated interim efficacy data from Part C of its Phase 2 THIO-101 trial evaluating ateganosine as a third-line treatment for advanced non-small…NasdaqMAIA, CFR
- MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung CancerMAIA advances novel telomere-targeting agent under FDA’s Fast Track designationGlobeNewswire
- Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal(RTTNews) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech and pharmaceutical…NasdaqABBV, AZN, CMMB, GMAB